HTA ID Drug Brand Indication Assessment status Date
- Insulin aspart NovoRapid® FlexTouch ® For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Rapid Review Complete 28th August 2014
- Insulin Degludec Tresiba® Treatment of diabetes mellitus Assessment process complete 6th May 2015
- Insulin degludec/liraglutide (IDegLira) Xultophy® For the treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or in combination with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) or basal insulin does not provide adequate glycaemic control. Rapid Review Complete 18th October 2016
- Insulin Glargine Abasaglar® For the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Rapid Review Complete 12th October 2015
- Insulin Glargine U300 Toujeo® for the treatment of diabetes mellitus in adults. Rapid Review Complete 2nd July 2015
- Ipilimumab Yervoy® For the treatment of advanced (unresectable or metastatic) melanoma in adult patients who have received prior therapy. Assessment process complete 6th September 2011
24023 Iptacopan Fabhalta® Iptacopan is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. Rapid Review Complete 16th July 2024
- Iron (III) isomaltoside 1000 Diafer® For the treatment of iron deficiency in patients with chronic kidney disease on dialysis, when oral iron preparations are ineffective or cannot be used. Rapid Review Complete 20th November 2015
- Iron (III) isomaltoside 1000 Monover® For the treatment of Iron deficiency anaemia when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly. Rapid Review Complete 20th November 2015
- Iron isomaltoside 1000 MonoVer® For the treatment of iron deficiency anaemia in the following circumstances: When oral iron preparations are ineffective or cannot be used and where there is a clinical need to deliver iron rapidly. Rapid Review Complete 2nd February 2011
23024 Isatuximab Sarclisa® Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone, is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Rapid Review Complete 25th May 2023
- Isavuconazole Cresemba® For the treatment of invasive aspergillosis Rapid Review Complete 11th May 2016
- Isavuconazole Cresemba® For the treatment of mucormycosis in adult patients for whom amphotericin B is inappropriate. Rapid Review Complete 11th May 2016
25016 Isavuconazole Cresemba® Isavuconazole (Cresemba®is indicated for patients from one year of age to < 18 years for the treatment of invasive aspergillosis, and mucormycosis in patients for whom amphotericin B is inappropriate. Rapid Review Complete 25th March 2025
23031 Itopride Hydrochloride Progit® Treatment of gastrointestinal symptoms of functional dyspepsia caused by reduced gastrointestinal motility. Rapid Review Complete 7th July 2023
20027 IUB™ Ballerine® IUB™ Ballerine® MIDI 15mm diameter SCU300B For intrauterine contraception for up to five years. Rapid Review Complete 29th July 2020
20062 IUB™ Ballerine® IUB™ Ballerine® MIDI 15mm diameter SCU300B For intrauterine contraception for up to five years. Rapid Review Complete 17th February 2021
- Ivacaftor Kalydeco® For the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation Assessment process complete 1st February 2013
- Ivacaftor Kalydeco® For the treatment of children with CF aged 2 years and older and weighing less than 25 kg who have one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. Assessment process complete 12th October 2016
- Ivacaftor Kalydeco® For the treatment of patients with cystic fibrosis aged 18 years and older who have the R117H mutation in the CFTR gene. Assessment process complete 5th January 2017
22022 Ivacaftor/tezacaftor/elexacaftor Kaftrio® Ivacaftor/tezacaftor/elexacaftor (Kaftrio®) in combination with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. NCPE Assessment Process Complete 9th February 2023
23015 Ivosidenib Tibsovo® To be used in combination with azacitidine, as indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy. Awaiting response from the Applicant 31st July 2025
23016 Ivosidenib Tibsovo® For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R 132 mutation who were previously treated by at least one prior line of systemic therapy NCPE Assessment Process Complete 7th March 2025
- Ixazomib Ninlaro® In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Assessment process complete 18th December 2017
- Ixekizumab Taltz® For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Rapid Review Complete 26th July 2016
- Ixekizumab Taltz® For the treatment of active PsA in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies Rapid Review Complete 20th November 2018
21046 Ketoconazole Ketoconazole HRA® For the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. Rapid Review Complete 13th December 2021
- Lacosamide Vimpat® As monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.  The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age). Rapid Review Complete 31st October 2017
__ Lanadelumab Takhzyro® For routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. Assessment process complete 26th June 2020
- Lapatinib Tyverb® For the treatment of women with previously treated advanced or metastatic HER2 positive breast cancer. Assessment process complete 28th January 2008
19050 Larotrectinib Vitrakvi® For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NCPE Assessment Process Complete 6th July 2023
21053 Latanoprost/Timolol Fixapost® In adults (including the elderly) for the reduction of intraocular pressure in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‐blockers or prostaglandin analogues. Rapid Review Complete 6th December 2021
25008 Lebrikizumab Ebglyss® Lebrikizumab (Ebglyss®) is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40kg who are candidates for systemic therapy. Rapid Review Complete 19th February 2025
24052 Lecanemab Leqembi® Lecanemab (Leqembi®) is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (Early Alzheimer’s disease) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology. Awaiting full HTA submission from Applicant 2nd July 2025
- Ledipasvir/sofosbuvir Harvoni® For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4)  in adults. Assessment process complete 20th November 2015
25047 Lenacapavir Sunlenca® Lenacapavir (Sunlenca®) in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen. Rapid Review Complete 8th August 2025
- Lenalidomide Revlimid® For the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension). Rapid Review Complete 20th November 2015
- Lenvatinib Kisplyx® In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy. Rapid Review Complete 18th May 2017
22057 Lenvatinib Kisplyx® For the treatment of adults with advanced renal cell carcinoma, in combination with pembrolizumab, as first-line treatment Rapid Review Complete 22nd September 2022
- Lenvatinib Lenvima® For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine. Rapid Review Complete 10th July 2015
- Lenvatinib Lenvima® As monotherapy for the treatment of adult patients with advanced or unresectable HCC who have received no prior systemic therapy. Rapid Review Complete 16th August 2018
- Lesinurad Zurampic® For the treatment of hyperuricaemia in adult patients with gout who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor. Assessment process complete 6th December 2018
- Letermovir Prevymis® For the prophylaxis of cytomegalovirus (CMV) reactivation or disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT). Assessment process complete 20th May 2020
25044 Levodopa Inbrija® Levodopa (Inbrija®) is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor. Rapid Review Complete 7th August 2025
- Levodopa 20mg/ml + carbidopa monohydrate 5mg intestinal gel Duodopa® For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted. Assessment process complete 14th June 2019
21068 Levodopa/carbidopa/entacapone intestinal gel Lecigon® For the treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson’s medicinal products have not given satisfactory results. Rapid Review Complete 17th February 2022
- Levofloxacin Quinsair® For the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with Cystic Fibrosis. Rapid Review Complete 2nd March 2016
- Levonorgestrel intrauterine delivery system LNG IUS 12 Kyleena® For contraception for up to 5 years. Rapid Review Complete 16th March 2017
- Levonorgestrel Intrauterine System Levosert® For contraception and for the treatment of heavy menstrual bleeding. Rapid Review Complete 23rd October 2019
- Levonorgestrel intrauterine system LNG-IUS Jaydess® For contraception for up to three years. Rapid Review Complete 26th March 2013